Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Article in Nature Communications (February 2024)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Article in Nature Communications (February 2024)
Article in Biomolecules (December 2023)
Article in Cell Biochemistry and Biophysics (October 2023)